DR510 / Huadong Medicine - LARVOL DELTA

DR510: A dual-masking T cell engager prodrug with single-site cleavage for balancing efficacy and safety in solid tumor therapy (ESMO 2025) - "Legal entity responsible for the study Zhejiang Doer Biologics Co., Ltd. Funding Zhejiang Doer Biologics Co., Ltd."

Clinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • IL6

A novel T-cell engager prodrug platform achieves dual masking by a single VHH domain for balancing efficacy and safety in solid tumor therapy (AACR-NCI-EORTC 2025) - "These preclinical data highlight our platform's ability to balance the therapeutic efficacy of TCEs with safety. Supported by these data, DR510 is now advancing toward clinical development for the treatment of EGFR-positive solid tumors."

Clinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • EGFR • IFNG • IL10 • IL2 • IL4 • IL6 • TNFA